Posted by Michael Wonder on 19 Sep 2017
Akcea announces filing of new drug submission for volanesorsen to Health Canada
12 September 2017 - Health Canada grants priority review for volanesorsen new drug submission filing.
Akcea Therapeutics Canada today announced the filing of a New Drug Submission (NDS) to Health Canada for volanesorsen, an investigational medicine for the treatment of familial chylomicronemia syndrome.
Health Canada has also granted priority review for the volanesorsen NDS. Priority review provides for the "fast-tracking" of eligible regulatory filings in Canada intended for the treatment, prevention or diagnosis of serious, life-threatening or severely debilitating diseases or conditions.
